Abstract
Melanoma is the leading fatal disease originating from the skin. Serious adverse effects of conventional therapies make the seeking of new options of treatment necessary. Immunotherapies represent an alternative and, among them, the anti-angiogenic approaches are promising. The vascular endothelial growth factor (VEGF) plays a critical role in the angiogenic process. Bevacizumab is a huma…